Bridging HER2 Testing and Treatment: Closing the Gap Between Diagnosis and HER2-Targeted Therapy Across 22 Solid Tumors

New real-world analysis of 220,069 samples across ten cancer types maps HER2 expression well beyond breast and gastric tumors. Drawing on NeoGenomics’ NeoNucleus™ database, this white paper quantifies HER2-positive and HER2-low prevalence, testing growth, and resistance-linked co-mutations—critical context as HER2-targeted therapy goes tumor-agnostic.